We Apply Innate Immunity Research to Assay Development for Pharmaceutical & Diagnostic Testing
The importance of the innate immune system in host defense has been increasingly recognized over the last ten years. During this time, IBT has been a recognized leader in the field of innate immunity research and testing.
- About Innate Immunity
- Current Innate Immunity Testing & Research
- Mannan-Binding Lectin (MBL)
- Toll-Like Receptors
- MBL-Associated Serine Proteases (MASPs)
- Natural Killer Cells
- Ficolins (H- and L-)
- Neutrophils, Monocytes and Macrophages
- Cathelicidins
- Dendritic Cells
- ß-Defensins
The innate immune system, which is the body’s first line of defense, is “hardwired” to be the rapid response force to combat microbial invasion. The innate immune response is triggered when pathogen-associated molecular patterns (PAMPs), which are presented exclusively on microbes including bacteria, fungi, parasites and viruses, bind to receptors such as Toll-Like Receptors (TLRs), mannose receptors and complement receptors on host cells.
The critical result of this interaction is the rapid recruitment and upregulation of neutrophils, monocytes, macrophages, complement factors, cytokines and antimicrobial peptides to the site of infection. Deficiency in any of the key components within the innate immune system has been shown to increase a patient’s susceptibility to infection.
IBT conducts industry-leading research to determine how deficiencies in the innate immune system increase patients' susceptibility to infection. From this knowledge, we develop novel clinical tests that assess the effects of drugs or other compounds on the innate immune system. With our active research and development program, IBT will continue to expand our test menu in this exciting area.
IBT offers both standard and customized contract testing and assay development services tailored specifically to the individual needs of our pharmaceutical and biotechnology clients.
The following research topics and tests are being actively investigated at IBT:






